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Macrophages: Central regulators of hepatic ﬁbrogenesis and
ﬁbrosis resolution
Prakash Ramachandran, John P. Iredale⇑
MRC Centre for Inﬂammation Research, University of Edinburgh, UK
Summary
Hepatic ﬁbrosis is the common end point to chronic injury of var-
ied aetiology. There is now excellent evidence in both human
studies and animal models that liver ﬁbrosis is a bidirectional
process with a signiﬁcant reversible component. The hepatic stel-
late cell (HSC), following activation to a myoﬁbroblast phenotype,
is the principal cell producing extracellular matrix (ECM) during
ﬁbrogenesis and is the main source of TIMP-1, which inhibits the
endogenous matrix-degrading activity of matrix metalloprotein-
ases (MMPs), thus promoting scar deposition. Furthermore, apop-
tosis of activated HSCs is a critical feature of scar resolution.
However, emerging evidence indicates that it is the hepatic mac-
rophage that is the master regulator of this dynamic ﬁbrogene-
sis–ﬁbrosis resolution paradigm.
Macrophages can promote ﬁbrogenesis
The key role of macrophages in promoting hepatic ﬁbrogenesis
has been demonstrated in a number of studies. Transgenic ani-
mals, deﬁcient in the principal macrophage chemokine CCL2-
CCR2 axis [1], show reduced monocyte/macrophage inﬁltration
following chronic hepatic injury and are protected from ﬁbrogen-
esis. Furthermore, utilising a CD11b-DTR system in mice, selec-
tive depletion of macrophages during ongoing injury causes a
reduction in ﬁbrosis [2]. Additional work has identiﬁed a speciﬁc
Gr-1high subset of hepatic macrophages, derived from recruit-
ment of inﬂammatory monocytes in a CCR2-dependent manner,
as being the principal pro-ﬁbrotic population [3].
So how do macrophages mediate this effect? Closer analysis of
ﬁbrotic tissue in human disease and animal models identiﬁes
macrophages closely associated with the hepatic scar, directly
apposed to the activated HSCs. Macrophages are a rich source
of soluble mediators which can act on the HSCs to induce a
pro-ﬁbrotic phenotype. Speciﬁcally, macrophages can produce
and activate the archetypal pro-ﬁbrotic cytokine TGF-b, which
acts to increase myoﬁbroblast ECM and TIMP-1 production [3].
Additionally, hepatic macrophages can produce PDGF (a potent
stimulator of myoﬁbroblast proliferation), IL-1b and TNF-a
(pro-inﬂammatory cytokines) and a number of chemokines
which can induce further inﬂammatory cell recruitment to per-
petuate the pro-inﬂammatory pro-ﬁbrotic stimulus [4] (Fig. 1).
Macrophages are critical for ﬁbrosis resolution
Emerging evidence now clearly demonstrates that macrophages
also have a pivotal role in ﬁbrosis resolution. Selective depletion
of hepatic macrophages during the spontaneous recovery phase
after chronic CCl4-induced ﬁbrosis caused a clear failure of hepa-
tic scar remodelling [2]. Additionally, in CCR2 knockout mice,
despite a lower baseline ﬁbrotic response, there is diminished
ﬁbrosis resolution following the cessation of injury [1]. Finally,
the administration of exogenous macrophages during ongoing
hepatic injury can have a signiﬁcant anti-ﬁbrotic effect [5].
The mechanisms governing the role of the macrophage in
ﬁbrosis resolution are still not fully deﬁned and are likely to be
multi-factorial, given the immense plasticity in macrophage phe-
notypes. We have previously shown that macrophages are a rich
source of scar degrading MMPs, particularly MMP-13, during the
resolution phase in vivo [6]. Macrophages are also capable of pro-
ducing a number of factors, such as MMP-9 or TRAIL, which can
promote HSC apoptosis, although a functional role for this mech-
anism remains to be proven. Additionally, loss of the pro-inﬂam-
matory pro-ﬁbrotic signals expressed by macrophages during
ﬁbrogenesis might alter the local milieu to favour ﬁbrosis resolu-
tion. Indeed, in elegant work by the Tacke group, they deﬁned
that CX3CL1 produced by hepatocytes and HSCs in the inﬂamed
liver could signal to inﬁltrating monocyte-derived macrophages
via the CX3CR1 receptor, inducing macrophage survival and an
anti-inﬂammatory phenotype to limit the degree of hepatic
inﬂammation and ﬁbrosis [7]. Macrophages in inﬂamed tissue
also perform the phagocytosis of cellular debris, which removes
potential pro-inﬂammatory signals and may in turn alter macro-
phage phenotype causing increased MMP expression and
enhanced matrix degradation [8]. Furthermore, in renal ﬁbrosis
studies serum amyloid P (SAP) protein, a circulating serum pro-
tein, binds to apoptotic cells, opsonising them and then signalling
via Fcc receptors on monocytes and macrophages, inducing an
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anti-inﬂammatory phenotype with increased IL-10 production
and consequent protection from ﬁbrosis [9] (Fig. 1).
The identity of the pro-resolution macrophage
Clearly, macrophages can show signiﬁcant functional differences
in their effects on hepatic ﬁbrosis. It is well described that mac-
rophage populations are heterogeneous in the ﬁbrotic liver, with
distinct contributions from resident Kupffer cells and recruited
monocytes [2]. Indeed, signiﬁcant macrophage heterogeneity
has been identiﬁed by ﬂow cytometry analysis of freshly-isolated
human liver, with a CD14+ CD16+ population accumulating in the
ﬁbrotic liver and correlating with worsening ﬁbrosis [10]. How-
ever, what remains elusive is the identity of the macrophage sub-
set mediating ﬁbrosis resolution. Speciﬁcally, do pro-resolution
macrophages derive from resident or recruited cells? Does local
macrophage proliferation contribute to the formation of distinct
populations? Are they formed from pro-ﬁbrotic macrophages
by a phenotypic switch in situ? What factors induce this switch?
What genes do they express to mediate their effect? Answers to
these questions in animal models will also permit identiﬁcation
and characterisation of pro-resolution macrophages in situ in
the human cirrhotic liver. Furthermore, a greater understanding
will enable the development of novel therapeutic strategies to
manipulate macrophage phenotype in vivo and accelerate ﬁbrosis
resolution.
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Fig. 1. Macrophages: Central regulators of hepatic ﬁbrogenesis and ﬁbrosis resolution.
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